Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A.

J Biol Chem. 2011 Dec 2;286(48):41273-85. doi: 10.1074/jbc.M111.293266.

2.

A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.

Hong KW, Kim CG, Lee SH, Chang KH, Shin YW, Ryoo KH, Kim SH, Kim YS.

J Biotechnol. 2010 Jan 1;145(1):84-91. doi: 10.1016/j.jbiotec.2009.09.023.

PMID:
19828124
3.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.

Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M.

Neoplasia. 2012 Nov;14(11):1023-31.

4.

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD.

J Mol Biol. 2012 Sep 28;422(4):532-44. doi: 10.1016/j.jmb.2012.06.014.

5.

DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage.

Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M.

J Mol Biol. 2009 Oct 30;393(3):598-607. doi: 10.1016/j.jmb.2009.08.014.

PMID:
19683003
6.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
7.

Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

PMID:
16288119
8.

Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.

Chang C, Takayanagi A, Yoshida T, Shimizu N.

Exp Cell Res. 2013 May 1;319(8):1146-55. doi: 10.1016/j.yexcr.2013.03.002.

PMID:
23499740
9.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

10.

Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.

Steiner D, Forrer P, Plückthun A.

J Mol Biol. 2008 Oct 24;382(5):1211-27. doi: 10.1016/j.jmb.2008.07.085.

PMID:
18706916
11.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

12.

Selection and characterization of Her2 binding-designed ankyrin repeat proteins.

Zahnd C, Pecorari F, Straumann N, Wyler E, Plückthun A.

J Biol Chem. 2006 Nov 17;281(46):35167-75.

13.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW.

MAbs. 2011 Nov-Dec;3(6):584-95. doi: 10.4161/mabs.3.6.17955.

14.

DARPins: a true alternative to antibodies.

Stumpp MT, Amstutz P.

Curr Opin Drug Discov Devel. 2007 Mar;10(2):153-9. Review.

PMID:
17436550
15.

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM.

Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659. Erratum in: Cancer Res. 2009 Dec 1;69(23):9156. Cancer Res. 2008 Aug 15;68(16):6859. Soler, Roman Perez [corrected to Perez-Soler, Roman].

16.

Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.

Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A.

Structure. 2013 Nov 5;21(11):1979-91. doi: 10.1016/j.str.2013.08.020.

17.

A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.

Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM.

Int J Cancer. 2011 Oct 15;129(8):2013-24. doi: 10.1002/ijc.26145.

18.

A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.

Müller N, Hartmann C, Genssler S, Koch J, Kinner A, Grez M, Wels WS.

Int J Cancer. 2014 Jun 1;134(11):2547-59. doi: 10.1002/ijc.28585.

19.

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M.

Eur J Cancer. 2010 Jun;46(9):1703-11. doi: 10.1016/j.ejca.2010.03.005.

PMID:
20399639
20.

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.

Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG.

Gastric Cancer. 2012 Jul;15(3):252-64. doi: 10.1007/s10120-011-0102-9.

PMID:
22011788

Supplemental Content

Support Center